Trial site
Hospital Nove de Julho
São Paulo, 01409902, BrazilNot linked to an institution yet
- 7running trials
- 2closed trials
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 23 trials
- Status
- Active, not recruiting6 trials
- Completed2 trials
- Recruiting1 trial
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- Bayer1 trial
- Cardiol Therapeutics Inc.1 trial
- Daiichi Sankyo1 trial
- Genmab1 trial
Running trials
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094· Phase 3· Genmab· Source
Active, not recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
NCT06578247· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
NCT05242471· Phase 2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error